A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 27, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Patients With Candidemia and/or Invasive Candidiasis

Interventions

DRUG

HRS9432

Dosing frequency: intravenously once week

DRUG

Caspofungin Acetate for Injection

Dosing frequency: D1 70mg，followed by 50mg intravenously once daily

Trial Locations (1)

RECRUITING

The First Affiliated Hospital Of University Of South China, Hengyang

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY